July 09, 2008 05:03 ET

DIREVO announces transfer of patents from Evotec

COLOGNE, GERMANY--(Marketwire - July 9, 2008) - DIREVO Biotech AG announced today that it has entered into an agreement with Evotec under which Evotec will transfer certain patents to DIREVO that are currently licensed by DIREVO. Such patents protect key components of DIREVO's unique and proven protein/strain engineering platform. Using this platform, DIREVO develops products both independently and with global leaders such as AstraZeneca/MedImmune and Pfizer, as well as Danisco/Genencor and Nestlé.

"This is a very important milestone for the company, because DIREVO now owns essential parts of intellectual property protecting its technology" said Dr. Thomas von Rüden, CEO of DIREVO. "This will give us much greater flexibility in the company's future corporate development, e.g., it will allow us to spin out legal entities able to focus and further develop and customize the technology in their own markets"


DIREVO Biotech AG generates superior bioengineered products and processes for industrial and pharmaceutical markets by enhancing nature's potential. The Company's portfolio includes optimized proteins, optimized bioprocesses and other bio-molecules, in research, in commercial development and on the market. DIREVO develops products both independently and with global leaders such as Danisco/Genencor, Nestlé, AstraZeneca/MedImmune and Pfizer. DIREVO Biotech is committed to a tailored approach to addressing customer needs and market opportunities.

DIREVO's biopharmaceutical business generates improved second generation therapeutics and discovers and optimizes novel first-generation therapeutics. DIREVO offers early stage partnering from internal therapeutic antibody and protease discovery programs as well as collaborations on the optimization of a wide range of therapeutic proteins.

DIREVO's industrial biotechnology business focuses on the food & feed and biorefineries markets. The Company provides solutions through discovery, development and scale up of enzymes and strains. Industrial biotechnology at DIREVO emphasizes environmental sustainability and the use of renewable resources. For example, our collaboration with Danisco A/S has yielded a significantly improved enzyme which is marketed as part of a Danisco/Genencor product.

DIREVO Biotech AG is privately held and located in Cologne, Germany. Additional information is available at:

Contact Information

  • Contact:
    DIREVO Biotech AG
    Dr. Thomas von Rüden, CEO
    Telephone: + 49 221 8887-121